Antroquinonol

Phase 2Small molecule

GGolden Biotechnology Corporation

Antroquinonol is one of 203 small molecule programs targeting Pancreatic Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

202

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic NeoplasmCompleted

Chronic HepatitisActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Atopic DermatitisActive, not recruiting

COVID-19Active, not recruiting

HypercholesterolemiaActive, not recruiting

Pancreatic NeoplasmPreclinical

Completed

Chronic HepatitisPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

HypercholesterolemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Antroquinonol

GGolden Biotechnology Corporation

Phase 2

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

SARS-COV-2 VACCINE

Moderna

Preclinical

2 5

Aprotinin

Bayer

Preclinical

1 6

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 7

Conventional

PPopulation Health Research Institute

Preclinical

1 8

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 9

Moderna COVID-19 Vaccine

Moderna

Preclinical

4 10

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy2 trials

Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects

Completed·GGolden Biotechnology Corporation·Phase 1·NCT01134016·13 enrolled

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

Completed·GGolden Biotechnology Corporation·Phase 2·NCT02047344·31 enrolled

Chronic Hepatitis2 trials

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

Completed·GGolden Biotechnology Corporation·Phase 2·NCT03625102·60 enrolled

A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

Unknown status·CCheng-Chung Wei·Phase 2·NCT04112147·60 enrolled

Atopic Dermatitis2 trials

A Trial of Antroquinonol in Patients With Atopic Dermatitis

Completed·GGolden Biotechnology Corporation·Phase 2·NCT03622463·14 enrolled

A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis

Terminated·—·Phase 2·NCT04110873·14 enrolled

Acute Myeloid Leukemia1 trial

Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients

Completed·GGolden Biotechnology Corporation·Phase 2·NCT03823352·12 enrolled

Hypercholesterolemia1 trial

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

Completed·GGolden Biotechnology Corporation·Phase 2·NCT02719028·120 enrolled

2 more indications

COVID-191 trial

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

Completed·GGolden Biotechnology Corporation·Phase 2·NCT04523181·124 enrolled

Pancreatic Neoplasm1 trial

A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

Completed·GGolden Biotechnology Corporation·Preclinical·NCT03310632·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Antroquinonol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antroquinonol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antroquinonol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Golden Biotechnology Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGolden Biotechnology Corporation

Antroquinonol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy2 trials

Chronic Hepatitis2 trials

Atopic Dermatitis2 trials

Acute Myeloid Leukemia1 trial

Hypercholesterolemia1 trial

COVID-191 trial

Pancreatic Neoplasm1 trial

References

Drug Info

Quick Facts

Related News